<DOC>
	<DOCNO>NCT01829841</DOCNO>
	<brief_summary>- Famitinib tyrosin-inhibitor agent target c-Kit , VEGFR2 , PDGFR , VEGFR3 , Flt1 Flt3 . Phase I study show toxicity manageable . - The purpose study compare efficacy safety profile Famitinib Sunitinib patient metastatic renal cell carcinoma .</brief_summary>
	<brief_title>A Study Famitinib Patients With Advanced Metastatic Renal Cell Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>Patients histologically confirm advanced renal cell carcinoma include clear cell component available surgery Firstline therapy secondline treatment ( secondline treatment e.g chemotherapy cytokine therapy firstline treatment failure resistant patient ) With measurable disease ( use RECIST1.0 standard conventional CT scan ≥ 20 mm , spiral CT scan ≥ 10mm , target lesion receive radiation therapy , cryotherapy ) Male female , age ≥18 ≤75 ECOG 01 Life expectancy ≥ 3 month Subjects receive surgery , chemotherapy , radiation therapy , cytokine treatment cause damage restore , time interval ≥ 4 week , wind completely heal Normal major organ function Signed date informed consent Previously receive targeted therapy metastatic renal cell carcinoma ( sunitinib , Sorafenib ) Past suffering cancer , cure basal cell carcinoma cervical carcinoma situ Participated clinical trial within four week A variety factor affect oral medication ( inability swallow , gastrointestinal resection , chronic diarrhea intestinal obstruction ) Known brain metastasis , spinal cord compression , cancer , meningitis , screen CT MRI examination reveal brain leptomeningeal disease Patients hypertension ( systolic blood pressure &gt; 140 mmHg , diastolic blood pressure &gt; 90 mmHg ) . Patients Class I , myocardial ischemia myocardial infarction , arrhythmia ( include QT interval ≥ 440ms ) class I heart failure . Urine protein ≥ + + confirm 24hour urinary protein &gt; 1.0 g Coagulopathy bleeding tendency ( active peptic ulcer ) receive thrombolytic anticoagulant therapy Previous hyperactivity / venous thromboembolic event , cerebrovascular accident ( include transient ischemic attack ) , deep vein thrombosis pulmonary embolism The preexist abnormal thyroid function , even case medication still maintain within normal range With history abuse psychotropic drug mental disorder Patients Hepatitis B Hepatitis C History immunodeficiency , include HIV test positive suffering acquire , congenital immunodeficiency disease , history organ transplantation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>MRCC</keyword>
	<keyword>Metastatic Renal Cell Cancer</keyword>
	<keyword>Famitinib</keyword>
	<keyword>Sunitinib</keyword>
</DOC>